Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer-Reference-Cited by-同舟云学术

Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer

Published:2011-04-05 Issue:1 Volume:128 Page:127-136
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Martin M.,Romero A.,Cheang M. C. U.,López García-Asenjo J. A.,García-Saenz J. A.,Oliva B.,Román J. M.,He X.,Casado A.,de la Torre J.,Furio V.,Puente J.,Caldés T.,Vidart J. A.,Lopez-Tarruella Sara,Diaz-Rubio E.,Perou C. M.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-011-1461-y.pdf

Reference66 articles.

1. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet 1998;352(9132):930–942

2. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365(9472):1687–1717

3. Henderson IC, Berry DA, Demetri GD et al (2003) Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976–983

4. Mamounas EP, Bryant J, Lembersky BC et al (2005) Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for nodepositive breast cancer: results from NSABP-B 28. J Clin Oncol 23:3686–3696

5. Martin M, Pienkowski T, Mackey J et al (2005) Adjuvant docetaxel for node positive breast cancer. N Engl J Med 352:2302–2313

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Breast cancer patient-derived microtumors resemble tumor heterogeneity and enable protein-based stratification and functional validation of individualized drug treatment;Journal of Experimental & Clinical Cancer Research;2023-08-18

2. Breast cancer patient-derived microtumors resemble tumor heterogeneity and enable protein-based stratification and functional validation of individualized drug treatment;2023-04-12

3. DNA Topoisomerase Targeting Drugs;Holland‐Frei Cancer Medicine;2022-10-21

4. PRMT5 regulates RNA m6A demethylation for doxorubicin sensitivity in breast cancer;Molecular Therapy;2022-07

5. Predictive value of topoisomerase II alpha protein for clinicopathological characteristics and prognosis in early breast cancer;Breast Cancer Research and Treatment;2022-03-16